Literature DB >> 12001995

New hope for an AIDS vaccine.

Harriet L Robinson1.   

Abstract

The twenty-first century has begun with considerable success for new AIDS vaccines in macaque models. A common feature of these vaccines is their ability to induce high-frequency CD8+ T-cell responses that control, rather than prevent, infection with HIV. The new vaccines, which include DNA vaccines and live viral vectors, are based on technologies that have been developed since the start of the AIDS epidemic. The ultimate promise of these vaccines will be realized only when efficacy trials in humans are conducted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001995     DOI: 10.1038/nri776

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  29 in total

1.  A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels.

Authors:  Niren Murthy; Mingcheng Xu; Stephany Schuck; Jun Kunisawa; Nilabh Shastri; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

2.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 3.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

4.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Development of an AIDS vaccine: a daunting epidemiological challenge.

Authors:  Neal Nathanson; Bonnie J Mathieson
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.